• Zentalis Pharmaceuticals Inc ZNTL.OQ reported a quarterly adjusted loss of 56 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 14 cents. The mean expectation of ten analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from -78 cents to -52 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Zentalis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 67 cents​.

• The company reported a quarterly loss of $48.28 million.

• Zentalis Pharmaceuticals Inc shares had fallen by 23.9% this quarter and lost 60.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00

This summary was machine generated from LSEG data May 14 at 09:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)